Biogen (BIIB) Cost of Revenue (2009 - 2026)

Biogen's Cost of Revenue history runs 18 years deep, the most recent figure standing at $776.9 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 28.41% year-over-year to $776.9 million; the TTM figure through Jun 2026 stood at $2.6 billion (up 6.16% YoY), while the FY2025 annual figure was $2.4 billion, up 4.06% from the prior year.
• Cost of Revenue for Q2 2026 stood at $776.9 million, up from $661.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $776.9 million in Q2 2026, with the low at $164.0 million in Q4 2022.
• The 5-year median for Cost of Revenue is $588.1 million (2023), against an average of $534.7 million.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue tumbled 42.48% in 2022, then jumped 255.79% in 2024.
• Biogen's Cost of Revenue stood at $164.0 million in 2022, then changed by 0.0% to $164.0 million in 2023, then surged by 255.79% to $583.5 million in 2024, then decreased by 15.08% to $495.5 million in 2025, then surged by 56.79% to $776.9 million in 2026.
• Business Quant data shows BIIB's Cost of Revenue at $776.9 million in Q2 2026, $661.0 million in Q1 2026, and $495.5 million in Q4 2025.